The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, especially for MS drugs, according to a new study. The study found that average out-of-pocket costs for drugs for MS increased by 217% over a nine-year period.
